---
title: "What's Going On With Gelteq Stock Friday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289627523.md"
description: "Gelteq (GELS) stock dropped 33.66% on Friday, reversing a previous 200% surge driven by profit-taking after extreme volatility. Despite the price decline, the company announced successful veterinary palatability trials conducted with Kemin Industries. The results confirmed Gelteq's technology effectively masks bitter flavors for canines, validating its commercial potential in animal health and strengthening discussions with strategic partners."
datetime: "2026-06-12T17:24:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289627523.md)
  - [en](https://longbridge.com/en/news/289627523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289627523.md)
generator: "portal-rs"
---

# What's Going On With Gelteq Stock Friday?

**Gelteq Limited** (NASDAQ:GELS) stock is trading lower on Friday. The stock is experiencing a stark pullback following a period of extreme volatility. On Thursday, GELS shares skyrocketed by nearly 200%, making it a prime target for profit-taking.

The downward price action on Friday reflects a classic post-rally comedown. This sharp reversal highlights the volatile nature of micro-cap biotechnology stocks following explosive momentum sessions.

## Veterinary Palatability Trials Prove Successful

The stock decline occurs despite positive operational news released by the company on Friday. Gelteq announced the successful completion of its veterinary palatability trials.

The company conducted these trials in collaboration with Kemin Industries, a leading U.S.-based global ingredient manufacturer.

The tests aimed to optimize flavor profiles and evaluate canine acceptance of products utilizing the proprietary Gelteq technology.

## Masking Bitter Flavors For Canines

During the trials, the company tested several products, including formulations containing natural bitter compounds that dogs normally reject.

According to the company, the results demonstrated strong canine acceptance and confirmed that Gelteq technology effectively masks bitter flavors while improving overall palatability.

The company notes that product acceptance is critical for animal therapeutics, and this data will guide future product optimization.

## CEO Highlights Commercial Potential

Management remains highly optimistic about how these results impact ongoing corporate discussions. In the announcement, **Nathan Givoni**, CEO of Gelteq, stated, “The successful completion of these trials represents an important milestone in validating Gelteq technology within the animal health sector.”

“The strong acceptance outcomes, including the ability to effectively mask bitter flavors while improving palatability, provide further evidence of the versatility and commercial potential of Gelteq technology across veterinary applications.”

Givoni added that the company believes this success “strengthens our ongoing discussions with potential strategic partners as we continue expanding our animal health pipeline.”

## Gelteq Price Action

**GELS Stock Price Activity:** Gelteq shares were down 33.66% at $1.01 at the time of publication on Friday, according to Benzinga Pro data.

*Photo via Shutterstock*

### Related Stocks

- [GELS.US](https://longbridge.com/en/quote/GELS.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [10:07 ETOG Anunoby Wants You to Take Your Cat to the Vet](https://longbridge.com/en/news/296504396.md)
- [Leading With Care: 25 Years of Meaningful Engagement](https://longbridge.com/en/news/296632497.md)
- [Earth Science Tech, Inc. (ETST) Acquires Zoolzy LLC to Drive Margin Expansion and Strategic Entry into the Veterinary Market | ETST Stock News](https://longbridge.com/en/news/296357540.md)
- [PetVivo to exhibit at 2026 Fetch Kansas City Veterinary Conference](https://longbridge.com/en/news/296256800.md)
- [09:48 ETAnimal Rescue Corps brings frontline perspective to push for effective cost-of-care laws for animals seized in cruelty cases](https://longbridge.com/en/news/296116738.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**